

Claims

1. A monoclonal antibody comprising
 - (a) a Light Chain CDR1 having the amino acid sequence of **SEQ ID NO:31**;
 - (b) a Light Chain CDR2 having the amino acid sequence of **SEQ ID NO:4**;
 - 5 (c) a Light Chain CDR3 having the amino acid sequence of **SEQ ID NO:5**;
 - (d) a Heavy Chain CDR1 having the amino acid sequence of **SEQ ID NO:6**;
 - (e) a Heavy Chain CDR2 having the amino acid sequence of **SEQ ID NO:7**; and
 - (f) a Heavy Chain CDR3 having the amino acid sequence of **SEQ ID NO:8**, or **SEQ ID NO:39**.
- 10 2. The monoclonal antibody according to claim 1 comprising
 - (a) a Light Chain CDR1 having the amino acid sequence of **SEQ ID NO:31**;
 - (b) a Light Chain CDR2 having the amino acid sequence of **SEQ ID NO:4**;
 - (c) a Light Chain CDR3 having the amino acid sequence of **SEQ ID NO:5**;
 - 15 (d) a Heavy Chain CDR1 having the amino acid sequence of **SEQ ID NO:6**;
 - (e) a Heavy Chain CDR2 having the amino acid sequence of **SEQ ID NO:7**; and
 - (f) a Heavy Chain CDR3 having the amino acid sequence of **SEQ ID NO:8**.
- 20 3. The monoclonal antibody according to claim 1 or 2, comprising
 - (a) a Light Chain comprising the amino acid sequence of **SEQ ID NO:16**; and
 - (b) a Heavy Chain comprising the amino acid sequence of **SEQ ID NO:11**.
- 25 4. The monoclonal antibody according to claim 1 comprising
 - (a) a Light Chain CDR1 having the amino acid sequence of **SEQ ID NO:31**;
 - (b) a Light Chain CDR2 having the amino acid sequence of **SEQ ID NO:4**;
 - (c) a Light Chain CDR3 having the amino acid sequence of **SEQ ID NO:5**;
 - (d) a Heavy Chain CDR1 having the amino acid sequence of **SEQ ID NO:6**;
 - (e) a Heavy Chain CDR2 having the amino acid sequence of **SEQ ID NO:7**; and
 - (f) a Heavy Chain CDR3 having the amino acid sequence of **SEQ ID NO:39**.
- 30

5. The monoclonal antibody according to claim 4 comprising
 - (a) a Light Chain comprising the amino acid sequence of **SEQ ID NO:16**;
 - (b) a Heavy Chain comprising the amino acid sequence of **SEQ ID NO:24**.

- 5 6. Use of the monoclonal antibody according to any one of claims 1 to 5 in the manufacture of a medicament for treating a tauopathy selected from the group consisting of Alzheimer's disease, Argyrophilic Grain Disease (AGD), Psychosis, particularly Psychosis due to AD or Psychosis in patients with AD, apathy due to AD or apathy in patients with AD, psychiatric symptoms of patients with Lewy body

10 dementia, Progressive Supranuclear Palsy (PSP), Frontotemporal dementia (FTD or variants thereof), TBI (traumatic brain injury, acute or chronic), Corticobasal Degeneration (CBD), Picks Disease, Primary age-related tauopathy (PART), Neurofibrillary tangle-predominant senile dementia, Dementia pugilistica, Chronic traumatic encephalopathy, stroke, stroke recovery, neurodegeneration in relation to

15 Parkinson's disease, Parkinsonism linked to chromosome, Lytico-Bodig disease (Parkinson-dementia complex of Guam), Ganglioglioma and gangliocytoma, Meningioangiomas, Postencephalitic parkinsonism, Subacute sclerosing panencephalitis, Huntington's disease, lead encephalopathy, tuberous sclerosis, Hallervorden-Spatz disease and lipofuscinosis.

- 20 7. Use of the monoclonal antibody according to any one of claims 1 to 5, in the manufacture of a medicament for the treatment of Alzheimer's disease.